| scholarly article | Q13442814 |
| P50 | author | Alastair Peter Greystoke | Q54317995 |
| P2093 | author name string | S A Mullamitha | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review | Q24289005 | ||
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field | Q24620628 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| A genetic model for colorectal tumorigenesis | Q27860582 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Smac/DIABLO and colon cancer | Q28236572 | ||
| Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. | Q54584514 | ||
| Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer | Q54614277 | ||
| The prevalence of PIK3CA mutations in gastric and colon cancer. | Q54655912 | ||
| A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy | Q56901570 | ||
| Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability | Q57338061 | ||
| Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy | Q61631846 | ||
| Randomized clinical trials in single patients during a 2-year period | Q72305075 | ||
| Influence of surgery on metachronous distant metastases and survival in rectal cancer | Q74083053 | ||
| Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study | Q79572431 | ||
| Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database | Q81149391 | ||
| Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) | Q81341430 | ||
| The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer | Q82445247 | ||
| Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer | Q84376822 | ||
| Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors? | Q85156612 | ||
| Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? | Q50181835 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. | Q51054700 | ||
| Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors | Q51467202 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer | Q52846071 | ||
| Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial | Q53232788 | ||
| Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes | Q54047534 | ||
| Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? | Q54361260 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies | Q29614869 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. | Q31171190 | ||
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors | Q33393931 | ||
| Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial | Q33415864 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability | Q33611147 | ||
| Targeted therapy in advanced colorectal cancer: more data, more questions. | Q33632982 | ||
| Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin | Q33729779 | ||
| Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes | Q33777433 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population | Q33947174 | ||
| The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy | Q33986683 | ||
| PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers | Q33987852 | ||
| Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare Data | Q34039306 | ||
| NRAS mutations are rare in colorectal cancer | Q34091172 | ||
| Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study | Q34102606 | ||
| Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients | Q34200852 | ||
| Trends in Colorectal Cancer Incidence Rates in the United States by Tumor Location and Stage, 1992–2008 | Q34244636 | ||
| Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials | Q34263106 | ||
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 | ||
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer | Q34621860 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. | Q34777582 | ||
| DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. | Q35031411 | ||
| KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications | Q35069989 | ||
| The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. | Q35584314 | ||
| Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours | Q35653933 | ||
| Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 | Q35729861 | ||
| Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution | Q35737549 | ||
| Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications | Q35836592 | ||
| Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer | Q35874805 | ||
| Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression | Q35882193 | ||
| Two colons-two cancers: paradigm shift and clinical implications | Q35964258 | ||
| Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative | Q36001501 | ||
| Apoptosis and chemo-resistance in colorectal cancer | Q36795425 | ||
| Diagnosing and exploiting cancer's addiction to blocks in apoptosis | Q37059647 | ||
| Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience | Q37081059 | ||
| Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy | Q37141948 | ||
| Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. | Q37157691 | ||
| Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. | Q37173288 | ||
| Significance of Bcl-xL in human colon carcinoma | Q37265616 | ||
| Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis | Q37404742 | ||
| Ras signaling and therapies | Q37548931 | ||
| More is less -- combining targeted therapies in metastatic colorectal cancer | Q37639898 | ||
| Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. | Q37706863 | ||
| Drugs targeting Bcl-2 family members as an emerging strategy in cancer | Q37786022 | ||
| Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications | Q37877012 | ||
| The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? | Q37892929 | ||
| Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer | Q37897726 | ||
| Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma | Q37944927 | ||
| Recent developments in treatment stratification for metastatic breast cancer | Q37950515 | ||
| Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics | Q37970854 | ||
| Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis | Q37977049 | ||
| Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. | Q37988465 | ||
| Trends in colorectal cancer incidence in Norway 1962-2006: an interpretation of the temporal patterns by anatomic subsite. | Q38449172 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial | Q39748379 | ||
| Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells | Q39870310 | ||
| c-FLIP: a key regulator of colorectal cancer cell death | Q40118519 | ||
| Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies | Q41923524 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial | Q42948960 | ||
| Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy | Q43208381 | ||
| The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. | Q43233321 | ||
| Variations in demography and prognosis by colon cancer location | Q44409963 | ||
| Trends in colorectal cancer incidence rates in New Zealand, 1981-2004 | Q44413991 | ||
| Oncogenic PIK3CA mutations in colorectal cancers and polyps | Q44836946 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | Q46373510 | ||
| Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer | Q46578998 | ||
| c-FLIP inhibits chemotherapy-induced colorectal cancer cell death | Q46772732 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 564741 | |
| P577 | publication date | 2012-09-09 | |
| P1433 | published in | Gastroenterology research and practice | Q26853898 |
| P1476 | title | How many diseases are colorectal cancer? | |
| P478 | volume | 2012 |
| Q46719772 | Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer |
| Q38202166 | Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare? |
| Q53253114 | Colorectal cancer: dichotomous or continuum model? Perhaps, a combination of both: Table 1 |
| Q27011884 | Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology |
| Q40918277 | HER3 expression is correlated to distally located and low-grade colon cancer |
| Q89882336 | Investigation of sirtuin 1 polymorphisms in relation to the risk of colorectal cancer by molecular subtype |
| Q43902845 | Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery |
| Q36473022 | Male pattern baldness and risk of colorectal neoplasia. |
| Q24289344 | Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease |
| Q40876056 | Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy |
| Q36675320 | Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. |
| Q38722180 | Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications |
| Q47418712 | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study |
| Q37130603 | The role of personalized medicine in metastatic colorectal cancer: an evolving landscape |
Search more.